<DOC>
	<DOCNO>NCT01356160</DOCNO>
	<brief_summary>This Phase 2b , Randomized , Double-Blind , Placebo-Controlled Trial Evaluating Response Guided Therapy GS-5885 Alone Combination GS-9451 Peginterferon Alfa 2a Ribavirin Treatment Naïve Subjects Chronic Genotype 1 Hepatitis C Virus Infection .</brief_summary>
	<brief_title>GS-5885 Alone Combination With GS-9451 With Peginterferon Alfa 2a Ribavirin Treatment Chronic Genotype 1 Hepatitis C Virus</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Males female 1870 year age Chronic HCV infection Subjects must liver biopsy result ( ≤ 2 year prior Screening ) indicate absence cirrhosis . Monoinfection HCV genotype 1 HCV RNA &gt; 10^4 IU/mL Screening HCV treatment naïve Candidate PEG/RBV therapy Body mass index ( BMI ) 1836 kg/m2 , inclusive Agree use two form highly effective contraception method duration study 7 month last dose study medication . Females childbearing potential must negative pregnancy test Screening Baseline . Pregnant female male pregnant female partner Exceed define threshold leukopenia , neutropenia , anemia , thrombocytopenia , thyroid stimulate hormone ( TSH ) Diagnosis autoimmune disease , decompensated liver disease , poorly control diabetes mellitus , significant psychiatric illness , severe chronic obstructive pulmonary disease ( COPD ) , HIV , hepatitis B virus ( HBV ) , hepatocellular carcinoma malignancy ( exception certain resolve skin cancer ) , hemoglobinopathy , retinal disease , immunosuppressed . Subjects current use amphetamine , cocaine , opiate ( e.g. , morphine , heroin ) , ongoing alcohol abuse exclude . Patients stable methadone buprenorphine maintenance treatment least 6 month prior Screening may include study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>HCV</keyword>
	<keyword>Rapid Virologic Response</keyword>
	<keyword>Sustained Virologic Response</keyword>
	<keyword>Direct Acting Antiviral</keyword>
	<keyword>Combination Therapy HCV RNA</keyword>
	<keyword>Protease inhibitor</keyword>
	<keyword>Treatment naïve</keyword>
	<keyword>GS-5885</keyword>
	<keyword>GS-9451</keyword>
</DOC>